Parsifal poster feature

Parsifal at ASCO 2016

orange__line
Back to NEWS

At ASCO 2016, MedSIR presented its PARSIFAL phase II study design; a currently ongoing study that will end up enrolling more than 300 patients in over a half dozen countries. This RPH2 study compares the combination of palbociclib and fulvestrant versus palbociclib and letrozol in HR+/HER2- MBC.

parsifal poster

Share (and comment) this content

Back to NEWS

Botón CONTACT US